Novo Nordisk, the Danish pharmaceutical giant behind the popular weight-loss drug Wegovy, has announced a major restructuring plan that will eliminate 9,000 jobs worldwide. This move, the largest layoff in Denmark’s history, signals a dramatic shift for the company as it struggles to regain momentum in an increasingly competitive obesity and diabetes market.
Why is Novo Nordisk cutting jobs now?
The company has faced slowing sales growth and heavy pressure from U.S. competitor Eli Lilly, whose drug Zepbound recently overtook Wegovy in prescriptions. In response, Novo Nordisk is aiming to reduce costs and simplify its operations. The job cuts representing roughly 11.5% of its global workforce are expected to save about 8 billion Danish crowns ($1.25 billion CAD) annually.
How did Novo Nordisk lose its market lead?
Novo Nordisk surged to the top of Europe’s stock market in 2021 after Wegovy became the first highly effective obesity drug approved in the U.S. However, the company’s rapid hiring spree and expansion created complexity that has since backfired. Shares have fallen nearly 46% since the start of 2025, wiping billions off its market value and fuelling investor concerns.
What is the new CEO’s strategy?
Mike Doustdar, who took over as CEO just last month, is making this restructuring his first major move. His focus is clear:
- Streamlining operations
- Reinforcing leadership in diabetes and obesity treatments
- Boosting commercial execution
- Redirecting resources toward growth areas, including new obesity drug launches
The company is also preparing to roll out a pill version of Wegovy and exploring additional health benefits from its GLP-1 portfolio.
How will the savings be used?
Novo Nordisk says the billions saved from layoffs will not simply go into cost-cutting. Instead, the company plans to reinvest heavily into:
- Research and development
- Expanding manufacturing capacity
- Improving patient access globally
- Launching its drugs in new markets
The goal is to ensure “best-in-class” drug rollouts, especially as the company adapts to more consumer-driven sales models like telehealth platforms.
What challenges lie ahead?
Despite these plans, analysts remain cautious. Bank of America has suggested the company may issue yet another profit warning later this year, and investors are still waiting for signs that growth will rebound. Meanwhile, Eli Lilly continues to pose a formidable challenge, with its drugs gaining ground in the U.S. market.
What does this mean for patients and investors?
For patients, the restructuring is unlikely to change access in the short term, but future innovation and availability may benefit if reinvestment pays off. For investors, confidence remains shaky. Whether this bold move will stabilize Novo Nordisk’s trajectory or deepen concerns will become clearer when the company reports its third-quarter results in November.
Were You Impacted by the Novo Nordisk Layoffs?
If you’ve recently been let go as part of Novo Nordisk’s global restructuring, you may be entitled to more than the minimum severance being offered.
In Ontario, non-unionized employees including those in pharmaceutical, research, marketing, or corporate roles can often qualify for far greater compensation than the initial package provided. Factors such as your age, length of service, seniority, and total compensation determine what you’re legally owed. In some cases, severance entitlements can reach up to 24 months of pay.
At Whitten & Lublin Employment Lawyers, we regularly represent professionals in the corporate and life sciences sectors who are navigating sudden terminations. If you were affected by Novo Nordisk’s layoffs, call us at 647-951-7460 or contact us online to arrange a consultation and ensure you receive your full entitlements.
